drugset / Trial / NCT03212469
A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The study is an open label, multicentric, Phase I/II trial aiming to evaluate the safety, the clinical activity and abscopal anti-tumor effects of a therapeutic strategy associating Durvalumab in conjunction with SBRT or Durvalumab + Tremelimumab in conjunction with SBRT in patients with metastatic squamous cell carcinoma of head and neck, lung, or esophagus.
Timeline
- Start
- 2017-06-20
- Primary completion
- 2025-02-24
- Completion
- 2025-02-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | — |
| Subject | Tremelimumab | Monoclonal antibody | 75 mg | — |